Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia.

Peita L Graham-ClarkeBrett HauberMarco BoeriFelice LeonardiRussel T BurgeMaria FernandezAntje Tockhorn-Heidenreich Sandra Flórez

Published in: Patient preference and adherence (2020)

Despite the availability of biosimilar teriparatide in Colombia, patients expressed a strong preference for an originator biologic osteoporosis medicine over a biosimilar osteoporosis medicine, when the efficacy, safety, and cost of the two options were assumed to be the same.

Keyphrases

bone mineral density
postmenopausal women
end stage renal disease
rheumatoid arthritis
ejection fraction
chronic kidney disease
body composition
peritoneal dialysis
prognostic factors
patient reported outcomes
decision making